Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial - Test2 - elhamkhani - TriplyDB

Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial

Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial

http://www.wikidata.org/entity/Q28475986

about

Clinical Implications of Antiviral Resistance in Influenza Influenza treatment and prophylaxis with neuraminidase inhibitors: a review Influenza prevention and treatment in transplant recipients and immunocompromised hosts Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09 Two years after pandemic influenza A/2009/H1N1: what have we learned?The pharmacological management of severe influenza infection - 'existing and emerging therapies'.In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.Use of neuraminidase inhibitors in primary health care during pandemic and seasonal influenza between 2009 and 2013 Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives.A broadly neutralizing human monoclonal antibody is effective against H7N9.Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v.Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection.Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation.Perspective: emerging challenges in the treatment of influenza and parainfluenza in transplant patients Peramivir for the treatment of influenza.In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.Clinical use of approved influenza antivirals: therapy and prophylaxis.Case report: oseltamivir-induced resistant pandemic influenza A (H1N1) virus infection in a patient with AIDS and Pneumocystis jirovecii pneumonia.Newer influenza antivirals, biotherapeutics and combinations.The use of antiviral drugs for influenza: Guidance for practitioners 2012/2013 High influenza a virus infection rates in Mallards bred for hunting in the Camargue, South of France.How to approach and treat viral infections in ICU patients Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics Severe influenza treatment guideline.European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN.Pharmacokinetic properties of anti-influenza neuraminidase inhibitors.Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies A multiple imputation approach for MNAR mechanisms compatible with Heckman's model.A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir.Factors associated with non-persistence to oral and inhaled antiviral therapies for seasonal influenza: a secondary analysis of a double-blind, multicentre, randomised clinical trial.Emerging influenza antiviral resistance threats.Report of the first Asia-Pacific Forum on antiviral treatment of influenza, Asia-Pacific Alliance for the Control of Influenza, Bangkok, 14 June 2012.Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system.Therapy of H7N9 pneumonia: current perspectives.Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance Investigating Different Mechanisms of Action in Combination Therapy for Influenza

P2860

Q26782746-01054CEC-02F2-43F1-B59F-A13A74F852F7 Q26860032-1A536551-3848-4299-ADA4-C4BD7C52B0DF Q27011595-F0674C5B-AC01-49B4-9999-BDB1ED998416 Q28479036-FCCEBD88-327F-4679-AB19-6498D625B59C Q28480880-4ED50B3F-270E-45AC-9A26-13FD16F20378 Q30224656-EFD155BC-26A6-421D-BD29-A1C2F854C696 Q30243907-86D4306C-BC0F-473C-A89D-FC00551A4822 Q30356466-65ACB076-D24D-41F2-9138-1F93CC146D73 Q30371807-4C80E276-48EB-4B33-8490-D9BEAF43FFB8 Q30377702-729C493A-685D-4016-8EDB-8C9C94A49FDF Q30378035-18D29188-5631-4BA7-9F82-D6166A8EA7C1 Q30399530-5C5BA498-F2BA-4473-B873-92B3513727EA Q30406007-F8C9203F-B7E5-4D9E-B07F-50E897BBDF9D Q30407719-2FE0F9C3-1F6D-46AC-B735-1E20F5A0266E Q30412678-3AF05072-634A-47F5-ACA0-6EF1D0855DFA Q30413154-7EAB3573-BA56-42F6-8E9D-8267E814F289 Q30416440-8F22AE34-5912-444B-AED1-37F3D04B566E Q30425343-944D88E6-91B3-4346-8EF5-32337CBB7ED9 Q30429444-FE0976B9-364E-4F8D-82A4-C00A46DD42C2 Q30456363-06C26290-5747-4A5E-97A6-A14C565F6F90 Q34389114-B863C078-B404-43AA-92C1-4050814D45EA Q34405969-51C4E2CD-5BA1-4EB8-84B9-AACF518ABCDA Q34894660-2017EC02-0DE5-41D5-AD2A-090BDBE88BA4 Q35270303-50F7C4BA-AB6C-4275-9DEB-22B0C9C5BB1F Q36566014-F58F0875-6246-4964-93C5-1BA425B6F676 Q36965855-4DF9CFDF-7172-4A42-8B89-4AEB33AD59DF Q37549382-77F6E0D4-759F-41B2-A27B-D8BEC92EB97B Q37598807-F4BC5EB4-9759-4774-9134-ED0371961FDB Q38077827-980D4C3E-6594-4838-9DD6-F37FFE07BB63 Q38084212-C84DB22C-F98A-4E9D-9849-54A981DBB43D Q38633113-492E8D70-6737-4485-9EE3-239A823D7740 Q39985357-AE9BE2BD-FB30-4CA8-988E-FE932FD43ADE Q40065607-9E1B224A-F237-4E53-94F9-FA620B17ADD8 Q40126722-0DBF050A-E026-4AE7-9662-56E0684BFCB2 Q42725866-97D3BDDC-8CC7-4750-9765-64ED34F64FF9 Q43170817-F65E3339-DB4B-484C-B9D1-6922725D022D Q47593385-EC7C4A1D-EFF0-47E5-808B-9910210FE36B Q51861450-4E26CB67-DE09-4027-88B8-2B63EC641449 Q56985884-B0CAA3FD-CB57-45B9-8652-60E21C3C1066 Q58573517-F82BA83E-4246-483D-9E1F-AFFD7B8D00C1

P2860

Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial

http://www.wikidata.org/entity/Q28475986

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Efficacy of oseltamivir-zanami ...... mized placebo-controlled trial

@ast

Efficacy of oseltamivir-zanami ...... mized placebo-controlled trial

@en

Efficacy of oseltamivir-zanami ...... mized placebo-controlled trial

@nl

type

label

Efficacy of oseltamivir-zanami ...... mized placebo-controlled trial

@ast

Efficacy of oseltamivir-zanami ...... mized placebo-controlled trial

@en

Efficacy of oseltamivir-zanami ...... mized placebo-controlled trial

@nl

prefLabel

Efficacy of oseltamivir-zanami ...... mized placebo-controlled trial

@ast

Efficacy of oseltamivir-zanami ...... mized placebo-controlled trial

@en

Efficacy of oseltamivir-zanami ...... mized placebo-controlled trial

@nl

P1433

Q28475986-061974B0-3006-4E25-8B66-814C22B5798C

P1476

Q28475986-D8329B1B-DA86-4DCF-9F1C-0EDF2BFAB83A

P2093

Q28475986-0EE66B44-4BF7-477F-BC49-239F4324AB66

Q28475986-1A20EDEF-5ED8-4380-8164-2320C7C3D270

Q28475986-37CD0E5B-ACCE-4E59-B687-F486F6DD43F3

Q28475986-4839C682-B608-4337-9965-A4310CCD3F47

Q28475986-5AA57E5A-36E6-4800-9B92-1CCCAE0BFEAC

Q28475986-85F62966-110D-4D61-88F3-824524110968

Q28475986-8A767598-BFE8-4CD3-ADA5-F789CA913244

Q28475986-A115DC77-14B5-4027-8BEC-E57A96650335

Q28475986-DAEF78B7-E9E8-4493-813B-1B0E9AD65F80

Q28475986-DC92E433-F22C-42BB-8CA9-A7882B6D0D08

P2860

Q28475986-2C29035E-0AC6-4AA5-B3E7-D11AD82AC7E1

Q28475986-30B75AB9-8DF4-4F7B-AC51-D220EFD889E3

Q28475986-3B61E408-022A-40AD-B8AB-C7B242C14D3F

Q28475986-47042BEE-851D-4757-AAD2-F1F8FC3BDF15

Q28475986-5699F326-5CCE-47D4-9C56-A014E34B0F38

Q28475986-604B2223-0B98-4DA5-99F4-C4AAB8B42DAF

Q28475986-7085C21C-977A-452C-A035-3C3794B664A1

Q28475986-793E7784-C10E-48D6-BD4A-EA3EE5022359

Q28475986-7B8C661F-E99D-4316-8930-EB1E171170B0

Q28475986-8204B022-0AB5-4171-B947-A5BA9FD6D886

P304

Q28475986-7A8AE6D4-3269-4980-B1A7-6D595D95A6CD

P31

Q28475986-FC121892-0A92-4868-9288-C578DA478A0A

P356

Q28475986-7153AD90-6F18-4F2E-A99E-058E2C43E2F6

P407

Q28475986-8A7ED63E-16E1-4B51-BF37-D3587EBFD18E

P433

Q28475986-52ED6AA7-6042-4380-836B-40E7051E4C43

P478

Q28475986-0DE69753-FED1-4FAC-ACC7-6FA10F8E96B9

P50

Q28475986-4F618D86-2B78-4748-A414-9B13FD0F2DE2

Q28475986-A4780163-B444-4233-89F3-EF78960A4A1E

Q28475986-BC28DE8A-B09A-4982-9300-3519AE031A95

Q28475986-FB924ABC-B867-4114-9B9D-92FF69CEE857

P577

Q28475986-CF10304B-F6C6-4E68-9A42-3F83D9FDCC35

P5875

Q28475986-B6551026-E307-4783-BD60-AF9A1A6EC45B

P698

Q28475986-7F98EDCC-9BB9-4526-9B7B-0E16B4565FCB

P921

Q28475986-DE55832C-6944-45AE-82D6-68FE2AEF13A8

P932

Q28475986-8CE9A899-D716-41A5-A600-CCFC15C22A54

P356

JOURNAL.PMED.1000362

P1433

P1476

Efficacy of oseltamivir-zanami ...... mized placebo-controlled trial

@en

P2093

Anne Mosnier

http://www.w3.org/2001/XMLSchema#string

Annick Tibi

http://www.w3.org/2001/XMLSchema#string

Catherine Leport

http://www.w3.org/2001/XMLSchema#string

Corine Vincent

http://www.w3.org/2001/XMLSchema#string

Cécile Charlois-Ou

http://www.w3.org/2001/XMLSchema#string

Florence Tubach

http://www.w3.org/2001/XMLSchema#string

France Mentré

http://www.w3.org/2001/XMLSchema#string

Laurent Andreoletti

http://www.w3.org/2001/XMLSchema#string

Maude Bouscambert-Duchamp

http://www.w3.org/2001/XMLSchema#string

Thierry Blanchon

http://www.w3.org/2001/XMLSchema#string

P2860

Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro

Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis

Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy

Emergence of a novel swine-origin influenza A (H1N1) virus in humans

Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.

Influenza virus neuraminidase inhibitors.

Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.

The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.

Pandemic A(H1N1)2009 influenza virus detection by real time RT-PCR: is viral quantification useful?

P304

e1000362

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PMED.1000362

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Sylvie van der Werf

Sylvie van der Werf

P577

2010-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47756150

http://www.w3.org/2001/XMLSchema#string

P698

21072246

http://www.w3.org/2001/XMLSchema#string

P921

P932

2970549

http://www.w3.org/2001/XMLSchema#string